药物基本信息
通用名：抗PD-1单克隆抗体
适应症：以PD-1为靶点的免疫调节对抗肿瘤、抗感染、抗自身免疫性疾病及器官移植存活等。
市场需求
在临床上单抗药物的靶向性能够减少正常细胞受损，在减少副作用的同时还增强了药物疗效，所以目前在癌症、自身免疫性疾病、器官移植排斥等领域得到广泛应用。PD-1抗体/PD-L1抗体通过抑制、“狙击”PD-1/PD-L1,阻止其结合，促使抗癌细胞全力清剿癌细胞。
在肿瘤免疫疗法中，抗PD-1通路的抑制剂是最为成功的案例之一。通过使用抗体来抑制PD-1或PD-L1，患者的免疫系统能被激活，对肿瘤细胞产生杀伤。
在中国，尽管尚没有PD-1通路的抑制剂得到CFDA的批准，但不少新药已进入了临床试验阶段。据统计，在2013年1月1日到2017年4月6日期间，全球共有270项国际性临床试验，用以评估抗PD-1/PD-L1疗法在非小细胞肺癌治疗中的效果。在治疗肺癌方面，中国抗PD-1通路的免疫疗法，其临床试验仍处于较早期的阶段。
The basic information of drug
Common name: Anti PD-1 monoclonal antibody
Clinical use: Immunoregulation using PD-L1 as the target for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival.
Market demand
In clinical practice, monoclonal antibody targeting can reduce the damage of normal cells, while reducing side effects it also enhances the efficacy of drugs. So it is widely used in cancer, autoimmune diseases, organ transplant rejection and other fields in the current. PD-1 antibody / PD-L1 antibody prevent them combining and promote anti-cancer cells to clear the cancer cells by inhibiting and "sniping" PD-1 / PD-L1.
In tumor immunotherapy, anti-PD-1 pathway inhibitor is one of the most successful cases. By using the antibody to inhibit PD-1 or PD-L1, the patient's immune system can be activated to kill the tumor cells.
In China, although no PD-1 pathway inhibitors is been approved by CFDA, many new drugs have entered the clinical trial phase. According to statistics, in the January 1, 2013 to April 6, 2017, the global total of 270 international clinical trials to assess the effect of anti-PD-1 / PD-L1 therapy in the treatment of non-small cell lung cancer. In the treatment of lung cancer, the clinical trial of Chinese anti-PD-1 pathway of immunotherapy is still in the early stage.
(抗PD-1单克隆抗体作用机制,图片来源医药网)
